Literature DB >> 34850576

Antibody responses to BNT162b2 mRNA vaccine: Infection-naïve individuals with abdominal obesity warrant attention.

Alexis Elias Malavazos1,2, Sara Basilico1, Gianluca Iacobellis3, Valentina Milani4, Rosanna Cardani5, Federico Boniardi1, Carola Dubini1, Ilaria Prandoni1, Gloria Capitanio1, Laura Valentina Renna5, Sara Boveri4, Roberta Rigolini6, Matteo Carrara7, Giovanni Spuria7, Teresa Cuppone4, Aurelia D'acquisto4, Luca Carpinelli4, Marta Sacchi8, Lelio Morricone1, Francesco Secchi9,10, Elena Costa8, Lorenzo Menicanti4, Enzo Nisoli11, Michele Carruba11, Federico Ambrogi4,12, Massimiliano Marco Corsi Romanelli6,10.   

Abstract

OBJECTIVE: The excess of visceral adipose tissue might hinder and delay immune response. How people with abdominal obesity (AO) will respond to mRNA vaccines against SARS-CoV-2 is yet to be established. SARS-CoV-2-specific antibody responses were evaluated after the first and second dose of the BNT162b2 mRNA vaccine, comparing the response of individuals with AO with the response of those without, and discerning between individuals with or without prior infection.
METHODS: Immunoglobulin G (IgG)-neutralizing antibodies against the Trimeric complex (IgG-TrimericS) were measured at four time points: at baseline, at day 21 after vaccine dose 1, and at 1 and 3 months after dose 2. Nucleocapsid antibodies were assessed to detect prior SARS-CoV-2 infection. Waist circumference was measured to determine AO.
RESULTS: Between the first and third month after vaccine dose 2, the drop in IgG-TrimericS levels was more remarkable in individuals with AO compared with those without AO (2.44-fold [95% CI: 2.22-2.63] vs. 1.82-fold [95% CI: 1.69-1.92], respectively, p < 0.001). Multivariable linear regression confirmed this result after inclusion of assessed confounders (p < 0.001).
CONCLUSIONS: The waning antibody levels in individuals with AO may further support recent recommendations to offer booster vaccines to adults with high-risk medical conditions, including obesity, and particularly to those with a more prevalent AO phenotype.
© 2021 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society (TOS).

Entities:  

Mesh:

Substances:

Year:  2022        PMID: 34850576     DOI: 10.1002/oby.23353

Source DB:  PubMed          Journal:  Obesity (Silver Spring)        ISSN: 1930-7381            Impact factor:   5.002


  12 in total

1.  Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity.

Authors:  Zehra Kara; Rüveyda Akçin; Ahmet Numan Demir; Harika Öykü Dinç; Halit Eren Taşkın; Bekir Kocazeybek; Volkan Demirhan Yumuk
Journal:  Obes Surg       Date:  2022-07-08       Impact factor: 3.479

Review 2.  Impact of Obesity on Vaccination to SARS-CoV-2.

Authors:  Michaella-Jana C Nasr; Elizabeth Geerling; Amelia K Pinto
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-20       Impact factor: 6.055

3.  The effect of needle length and skin to deltoid muscle distance in adults receiving an mRNA COVID-19 vaccine.

Authors:  Thomas Hills; Aimee Paterson; Rebecca Woodward; Francis Middleton; Lauren H Carlton; Reuben McGregor; Sebastien Barfoot; Ciara Ramiah; Alana L Whitcombe; Victor M Zimbron; David Mahuika; Joshua Brown; Kate Palmer-Neels; Brittany Manning; Devanshi Jani; Brooke Reeves; Georgia T Whitta; Susan Morpeth; Richard Beasley; Mark Weatherall; Anthony Jordan; Peter McIntyre; Nicole J Moreland; S Ali Mirjalili
Journal:  Vaccine       Date:  2022-06-29       Impact factor: 4.169

4.  Use of heated tobacco products, moderate alcohol drinking, and anti-SARS-CoV-2 IgG antibody titers after BNT162b2 vaccination among Japanese healthcare workers.

Authors:  Shohei Yamamoto; Akihito Tanaka; Norio Ohmagari; Koushi Yamaguchi; Kazue Ishitsuka; Naho Morisaki; Masayo Kojima; Akihiko Nishikimi; Haruhiko Tokuda; Manami Inoue; Shiori Tanaka; Jun Umezawa; Ryo Okubo; Kunihiro Nishimura; Maki Konishi; Kengo Miyo; Tetsuya Mizoue
Journal:  Prev Med       Date:  2022-07-01       Impact factor: 4.637

Review 5.  BNT162b2 vaccine considerations for immunocompromised individuals: A global perspective.

Authors:  Hafsa Nazir Jatoi; Samina Abbas; Muhammad Saif Abbasi; Misha Asif Tauni; Shamas Ghazanfar; Mohammad Daniyal Zafar Malick; Muhammad Faiq Umar; Muhammad Junaid Tahir; Muhammad Sohaib Asghar; Ali Ahmed
Journal:  Ann Med Surg (Lond)       Date:  2022-05-17

6.  Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study.

Authors:  Jonas Herzberg; Bastian Fischer; Christopher Lindenkamp; Heiko Becher; Ann-Kristin Becker; Human Honarpisheh; Salman Yousuf Guraya; Tim Strate; Cornelius Knabbe
Journal:  Front Immunol       Date:  2022-03-04       Impact factor: 7.561

Review 7.  The Effect of Smoking on Humoral Response to COVID-19 Vaccines: A Systematic Review of Epidemiological Studies.

Authors:  Pietro Ferrara; Vincenza Gianfredi; Venera Tomaselli; Riccardo Polosa
Journal:  Vaccines (Basel)       Date:  2022-02-16

8.  Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies.

Authors:  M A Sughayer; L Souan; M M Abu Alhowr; D Al Rimawi; M Siag; S Albadr; M Owdeh; T Al Atrash
Journal:  Vaccine       Date:  2022-04-01       Impact factor: 4.169

Review 9.  Obesity and Leptin Resistance in the Regulation of the Type I Interferon Early Response and the Increased Risk for Severe COVID-19.

Authors:  Frits A J Muskiet; Pedro Carrera-Bastos; Leo Pruimboom; Alejandro Lucia; David Furman
Journal:  Nutrients       Date:  2022-03-26       Impact factor: 5.717

10.  IgG Antibody Response to the Pfizer BNT162b2 SARS-CoV-2 Vaccine in Healthcare Workers with Healthy Weight, Overweight, and Obesity.

Authors:  John T Bates; Andrew P Farmer; Michael A Bierdeman; Dallas R Ederer; Lauren S Carney; Denise D Montgomery; Seth T Lirette; Gailen D Marshall
Journal:  Vaccines (Basel)       Date:  2022-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.